Last reviewed · How we verify
NCT05341635: FASE2
FAst and SimplE COVID-19 Causing Virus SARS-CoV-2 Detection
trial testing Swab sampling in COVID-19 in 200 participants. Completed in 30 December 2020.
2 December 2020
Quick facts
| Lead sponsor | University of Milano Bicocca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 August 2020 |
| Primary completion | 2 December 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Swab sampling
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
University of Milano Bicocca
Who can join
Eligibility, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational study using biological material. The group of subjects in the study is represented by 100 male and female patients hospitalized with COVID-19 symptomatology and 100 non-hospitalized subjects with suspected COVID-19 diagnosis for a total of 200 patients. The expected recruitment time is about 6 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05341635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other University of Milano Bicocca trials
Trials by the same sponsor.
- NCT07257705 — Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital · NA · completed
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07424066 — Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05341635 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Milano Bicocca
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05341635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing